Literature DB >> 22342302

Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.

Susan L Tucker1, Lei Dong, Jeff M Michalski, Walter R Bosch, Kathryn Winter, James D Cox, James A Purdy, Radhe Mohan.   

Abstract

PURPOSE: To investigate whether the volumes of rectum exposed to intermediate doses, from 30 to 50 Gy, contribute to the risk of Grade ≥ 2 late rectal toxicity among patients with prostate cancer receiving radiotherapy. METHODS AND MATERIALS: Data from 1009 patients treated on Radiation Therapy Oncology Group protocol 94-06 were analyzed using three approaches. First, the contribution of intermediate doses to a previously published fit of the Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model was determined. Next, the extent to which intermediate doses provide additional risk information, after taking the LKB model into account, was investigated. Third, the proportion of rectum receiving doses higher than a threshold, VDose, was computed for doses ranging from 5 to 85 Gy, and a multivariate Cox proportional hazards model was used to determine which of these parameters were significantly associated with time to Grade ≥ 2 late rectal toxicity.
RESULTS: Doses <60 Gy had no detectable impact on the fit of the LKB model, as expected on the basis of the small estimate of the volume parameter (n = 0.077). Furthermore, there was no detectable difference in late rectal toxicity among cohorts with similar risk estimates from the LKB model but with different volumes of rectum exposed to intermediate doses. The multivariate Cox proportional hazards model selected V75 as the only value of VDose significantly associated with late rectal toxicity.
CONCLUSIONS: There is no evidence from these data that intermediate doses influence the risk of Grade ≥ 2 late rectal toxicity. Instead, the critical doses for this endpoint seem to be ≥ 75 Gy. It is hypothesized that cases of Grade ≥ 2 late rectal toxicity occurring among patients with V75 less than approximately 12% may be due to a "background" level of risk, likely due mainly to biological factors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22342302      PMCID: PMC3952553          DOI: 10.1016/j.ijrobp.2011.11.073

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement.

Authors:  Derek B Chism; Eric M Horwitz; Alexandra L Hanlon; Wayne H Pinover; Raj K Mitra; Gerald E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-01-01       Impact factor: 7.038

2.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.

Authors:  L J Boersma; M van den Brink; A M Bruce; T Shouman; L Gras; A te Velde; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-04-01       Impact factor: 7.038

3.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Authors:  G J Kutcher; C Burman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

4.  Complication probability as assessed from dose-volume histograms.

Authors:  J T Lyman
Journal:  Radiat Res Suppl       Date:  1985

5.  Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

Authors:  J M Michalski; J A Purdy; K Winter; M Roach; S Vijayakumar; H M Sandler; A M Markoe; M A Ritter; K J Russell; S Sailer; W B Harms; C A Perez; R B Wilder; G E Hanks; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

6.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.

Authors:  M W Skwarchuk; A Jackson; M J Zelefsky; E S Venkatraman; D M Cowen; S Levegrün; C M Burman; Z Fuks; S A Leibel; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

7.  Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.

Authors:  A Jackson; M W Skwarchuk; M J Zelefsky; D M Cowen; E S Venkatraman; S Levegrun; C M Burman; G J Kutcher; Z Fuks; S A Liebel; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

8.  Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer.

Authors:  Peter C M Koper; Wilma D Heemsbergen; Mischa S Hoogeman; Peter P Jansen; Guus A M Hart; Arendjan J Wijnmaalen; Marjolein van Os; Liesebeth J Boersma; Joos V Lebesque; Peter Levendag
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

9.  Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma.

Authors:  V A Benk; J A Adams; W U Shipley; M M Urie; P L McManus; J T Efird; C G Willett; M Goitein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-06-15       Impact factor: 7.038

10.  Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer.

Authors:  Carlo Greco; Chiara Mazzetta; Federica Cattani; Giampiero Tosi; Simona Castiglioni; Andrei Fodor; Roberto Orecchia
Journal:  Radiother Oncol       Date:  2003-11       Impact factor: 6.280

View more
  13 in total

1.  A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin.

Authors:  Mitchell S Anscher; Michael G Chang; Drew Moghanaki; Mihaela Rosu; Ross B Mikkelsen; Diane Holdford; Vicki Skinner; Baruch M Grob; Arun Sanyal; Aiping Wang; Nitai D Mukhopadhyay
Journal:  Am J Clin Oncol       Date:  2018-06       Impact factor: 2.339

2.  Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

Authors:  Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-03       Impact factor: 7.038

3.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

Review 4.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

5.  Late complications after radiotherapy for prostate cancer.

Authors:  H Jung; H-P Beck-Bornholdt; V Svoboda; W Alberti; T Herrmann
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

6.  Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.

Authors:  Bradford S Hoppe; Jeff M Michalski; Nancy P Mendenhall; Christopher G Morris; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Christopher R Williams; Meredith M Regan; Jonathan J Chipman; Catrina M Crociani; Howard M Sandler; Martin G Sanda; Daniel A Hamstra
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

7.  Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer.

Authors:  Natsuo Tomita; Norihito Soga; Yuji Ogura; Norio Hayashi; Hidetoshi Shimizu; Takashi Kubota; Junji Ito; Kimiko Hirata; Yukihiko Ohshima; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  J Radiat Res       Date:  2013-03-22       Impact factor: 2.724

8.  Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer.

Authors:  Yoshihiko Manabe; Yuta Shibamoto; Chikao Sugie; Fumiya Baba; Shiho Ayakawa; Aiko Nagai; Shinya Takemoto; Akihiro Hayashi; Noriyasu Kawai; Mitsuru Takeuchi; Satoshi Ishikura; Kenjiro Kohri; Takeshi Yanagi
Journal:  J Radiat Res       Date:  2013-10-17       Impact factor: 2.724

9.  Proctitis following stereotactic body radiation therapy for prostate cancer.

Authors:  Daniel Y Joh; Leonard N Chen; Gerald Porter; Aditi Bhagat; Sumit Sood; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Andrew W Ju; Simeng Suy; John Carroll; John H Lynch; Anatoly Dritschilo; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-12-12       Impact factor: 3.481

Review 10.  Proton therapy for early stage prostate cancer: is there a case?

Authors:  Tabitha Y Chan; Poh Wee Tan; Johann I Tang
Journal:  Onco Targets Ther       Date:  2016-09-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.